I think the layman's perception of the increase in survival (~13 months versus ~6 months) will make this look underwhelming. Nevertheless, it's important to remember that the incentives for clinical trials is to only include very late-stage patients who have exhausted all other options (faster trials, smaller sample sizes, surrogate endpoints, a shot at accelerated approval, ...). The fact that a treatment shows promise for these patients that are often in very poor health and considered "hopeless" by today's medicine is exceedingly rare, and the signal from this trial is indeed strong.
The (somewhat reasonable) hope is that patients 1. with earlier forms of pancreatic cancer (non-metastatic) 2. that can undergo surgery 3. together with a (neo)adjuvant treatment with these kras inhibitors, will end up having a much lower recurrence rate and a chance for a long, healthy life.
I think this is genuinely good news worth celebrating!
I have a friend who has a relatively good prognosis among pancreatic cancer patients but even still is facing the very real chance he wonât be here in 6 months. His wife gives birth to their second child in a month or so. I guarantee if it came down to it he would give literally anything to double his time with them.
"I guarantee if it came down to it he would give literally anything to double his time with them."
I'm deeply sorry about your friend, but I guarantee that this is not true. Nobody will give 'literally anything'. All his money? His house? His children's health?
Of course not. There is always a tradeoff in any treatment. My wife has chosen to stop the treatment that may have given her a few more months because those months would have been spent with the permanent side-effects of that treatment - nerve damage in this case. She would have no longer been able to paint, or cook, or enjoy what time she has left to her.
I think many of us would give anything to double whatever lifespan we have remaining at almost any point. Sorry about your friend!
âMan! Because he sacrifices his health in order to make money. Then he sacrifices money to recuperate his health. And then he is so anxious about the future that he does not enjoy the present; the result being that he does not live in the present or the future; he lives as if he is never going to die, and then dies having never really lived.â - Tenzin Gyatso
There is a conversational habit that many people have, of responding to a specific situation described by someone, with a generalization of that situation, or by bringing up one of their own similar experiences.
None of these responses are terrible, these responses are no doubt true. But in conversation, those are low bars.
These segues come across, and frankly are, very dismissive of the original particular circumstances brought up.
It is best to respond to specific situations, with something thoughtful and specific to them. The specific situation was not brought up as conversation filler or general smalltalk initiation, but for its specific import, so respect that.
Its an easy bad habit to have, but once it is recognized, it is fairly easy to break. And the result is people will find conversations with you much more thoughtful, caring, and pertinent.
Need examples beyond your own? Don't respond to the news that someone lost a leg with amputation statistics, or the time you almost lost a finger. Don't respond to someone's pain with trivia or tautology. Respond with specific comfort or help, or not at all.
[flagged]
Maybe I'm being clueless, but surely if the median survival time goes from 6 months to 13 months, the most likely way for that to happen would also be for a higher percentage of people to survive indefinitely - say, beyond five years? It would be weird if we had this existing life expectancy distribution with the median of the distribution at 6 months, and the pill pushed a ton of distribution mass to get the median to 13 months, and it somehow did that without getting more people to 2 years, 5 years, 10 years, ...
> surely if the median survival time goes from 6 months to 13 months, the most likely way for that to happen would also be for a higher percentage of people to survive indefinitely - say, beyond five years?
There's no way to know, unfortunately, but the trial data suggests otherwise [1]. This story is about anecdotes, and you should basically ignore it.
The trial for daraxonrasib was 16 months, with a median follow-up of 8.5 months, and the median progression-free survival in that trial was around 7 months. From this data alone, you can't really say anything about longer-term survival, but most patients appear to relapse well before 5 years.
Of course, that's still a benefit for a cancer where there's essentially no other options.
No one's interested in longer survival rates (except maybe patients). What people want is a CURE.
most of these phase iii cancer treatment studies look at median overall survival and usually it's an underwhelming single digit increase in months of life extension with varying quality of life.
it's a hard problem, sure, but i still think there should be endpoints that measure total remission or durable halt of progression and that words like "breakthrough" should be reserved for when those endpoints are met.
Generally agreed, but pancreatic cancer is so brutal and rare that basically anything that has a hint of efficacy is welcome.
sure, but i looked into this a bunch for mcrpc sometime back and it was the same thing. i suspect once it metastasizes it's pretty much the same story, there are a couple of hacks that can slow it down for a few months, but nothing really stops it.
i often wonder if a fundamentally new approach is needed. rather than static compounds and long drug trials, some sort of mechanism for establishing some safety properties rapidly and on demand (in vitro?) and then something that looks more like closed loop high frequency monitor and adjust customized interventional therapies that are synthesized and customized on the molecular level.
the mrna dream, but actually doing it, probably with ai and in vitro safety testing, probably.
For once, this isnât hyperbole. Metastatic pancreatic cancer hasnât had a meaningful new treatment in literally decades - itâs been brutal chemotherapy or slightly less brutal chemotherapy.
The new generation of KRAS inhibitors, of which daraxonrasib is just the first to make it to approval, is genuinely a practice-changing breakthrough.
It wonât cure people with metastatic disease, but it will help a lot live better lives for longer.
>Metastatic pancreatic cancer hasnât had a meaningful new treatment in literally decades
Not true. The folfirinox chemo regimen was invented a couple of years ago, and it significantly increased the life expectancy and quality of life for terminal pancreatic cancer patients.[0]
âit significantly increased the life expectancyâ
True. statistically it was significant.
Progression-free survival increased from 3 months to 6 months. (overall-survival increased from 7 months to 11 months).
Both statistically significant, and at the cost of increased toxicity during those additional 3 to 4 months of ââsignificantlyâ increased life expectancyâ
I donât get why this is down-voted.
To decide whether a survival of 3 to 4 months in exchange for increased toxicity (decreased quality of life during those few remaining months)
is âsignificantâ is a very nuanced decision between the patient and their physician.
Downvoted for mentioning that the life expectancy for metastatic pancreatic cancer was recently doubled. Apparently this new drug can't just be an advance, it has to be unprecedented, unique, and of course worth any price.
Brutal surgery too like the Whipple procedure. My sister's lasted 13 some hours and it probably gave her another year+ of life.
> For once, this isnât hyperbole.
Am I missing something?
From other sources:
> Median overall survival: 13.2 months versus about 6.6 to 6.7 months with chemotherapy.
This is absolutely NOT hyperbole, this has been an intractable disease for deacades, and the very first trial to show improvement is a lower bound on how effective the drug will be, not a full estimate.
First, this is a brutal drug, very hard to tolerate, and as better ways are found to manage side effects and to dial in the dosing, the treatment effects will increase.
Further, this is in metastatic pancreatic cancer, a stage of the disease where virtually all hope of a cure is gone for most. Any progress here will translate into bigger gains in earlier stages of the disease. We test new unproven therapies in metastatic cases like these because all other better options have been exhausted. And for decades, all those trials have been failures, this is the first time something has worked at all.
Additionally, this is just the first drug showing how to go after KRAS. Follow-on drugs, which some people call mere "me-too" drugs, will improve efficacy, have fewer side effects, and be more tolerable, all improving real-world results.
And as we learn to make KRAS treatments more tolerable, we'll also learn about how best to combine them with other existing chemotherapies, which requires lots of testing. Go to ASCO, and you'll see trial after trial after trial of small variations, trying to continuously improve existing treatments. It's a slow and brutal way to learn, but it's all we've got.
So if you only look at 13.2 months versus 6.7 months, yes, you are missing something! This is like discovering a whole new vein of gold ore to mine. We don't know where it will lead or how big it is, but what we can see right now is far far more than 13.2 / 6.7.
Doubling life expectancy on a form of cancer infamous as a death sentence.
I don't see that as a breakthrough.
Merely counting months does not do much - you'd have to count the quality of these months too.
> Doubling life expectancy on a form of cancer infamous as a death sentence.
Would you say the same thing if it were doubled from five minutes to ten minutes? Who cares about doubling? It's the 7.5 months that's the point. And 7.5 months is what it is.
For the low price of 40k a month, and you still get the same death sentence
Everything is relative. A few more months of life with less pain and more energy to spend it with family surely is a breakthrough for many patients and for the doctors treating them.
But where does it imply less pain? Plus, which pain exactly? Chemotherapy also leads to pain. Prolonging treatment can cause more pain then.
I don't see that as a breakthrough.
At the February 2026 data cutoff (median follow-up of 8.5 months), the median overall survival for daraxonrasib was 13.2 months, with a 95% confidence interval of 10.0 months to "not estimable". In contrast, the chemotherapy group's survival data had matured enough to lock in a tight confidence interval of 5.8 to 8.0 months.
So, it could be that the new drug is much much better, but they couldn't tell at the time because they only were trying to say that it was significantly better then chemotherapy.
> It wonât cure people with metastatic disease, but it will help a lot live better lives for longer.
Cancer is a problem that can be solved, and it needs to be solved asap. Cancer too often gets either relegated to "Actually, statistically it's very unlikely" by people who don't have it or stylized to the God of Death that unlike other illness we won't solve anytime soon. There is no time to be lost tackling with AI. Dario gets it. Had cancer himself and his father passed away from it.
The thing that makes cancer such a hard problem is that cancer is really a collection of diseases. There's, what, like over a hundred of them? And one organ can produce several unrelated cancers too. I do hope AI will actually be able to figure out the commonalities between all of them and a potential path for a possible even somewhat-universal solution, but I at least don't even know if a universal "cure" is even possible. Granted, my knowledge of biology with respect to cancers is pretty limited.
Cancer is a mutation of cells. There might be 100 known cancers that present in humans, but in theory any mutation can lead to cancer.
Unless we can reliably sign our cells like we do our binaries, we ain't "solving" cancer.
300 answers to unsolved problems were dropped all at once by a frontier lab
there doesnât even need to be a commonality, all will get solved
I hear ML researchers are even picking up smoking again
Honestly with all the bad press, I'm still determined and hope for a better future where this becomes reality. I just hope the focus shifts towards that, it would be an incredible achievement.
Cancer can be solved, and that's one thing I agree with Dario on. (His scare tactics and gatekeeping on the other hand actually slow down research.)
Agreed, if this was Dario's priority then there have been numerous missteps along the way that did more harm than good.
Its actually crazy all of these threads end up being about how good AI is, when the post has 0 to do with AI.
Which cancer? I ask because the specific thing preventing âa cancer cureâ is the fact that cancers are only vaguely related. Itâs like saying âbroken bone is a problem that can be solved.â
Yes, it can, but to imply itâs simply one disease is missing completely the exact reason why itâs so hard to cure.
In case others are wondering, it looks like this is a different story than this recent one:
Pancreatic cancer halted by virus injection in three patients - https://news.ycombinator.com/item?id=50563066 - Nov 2026 (157 comments)
Yes, FOLFIRINOX is a combination of chemotherapeutic agents.
Which is very different from being administered an adenovirus (VRT106) that recognizes a receptor often expressed on cancer cells (MXRA8), that after âinfectingâ the cell triggers direct oncolysis and indirect immunogenic responses.
Oh, I just assumed they were the same, incredible that there's now two very promising approaches for pancreatic cancer..!
There's also incremental improvements in chemo therapy and radiation therapy. Example: Elmedix and its heat treatment.
Does the -ib medication suffix have meaning? I know -ab medications like Benralizumab, Canakinumab, etc are monoclonal antibodies. The only -ib I can remember other than this new one is Imatinib, which is also a cancer treatment, so maybe it's to do with cancer?
People who pay a lot of attention to US news might know this as the therapy former senator and UF president Ben Sasse is taking.
âLast week, the former senator from Nebraska Ben Sasse announced that his Stage 4 pancreatic cancer had developed resistance to a cutting edge treatment.â
https://www.nytimes.com/2026/09/30/science/pancreatic-cancer...
Irrelevant aside, but that's a nice garden path sentence. My brain threw a couple of exceptions trying to parse what a "therapy former senator" is before finally realizing it's "the therapy [...] Ben Sasse is taking".
My former boss, one of the nicest, kindest and most jovial guys I've ever known, had pancreatic cancer. He quite literally wasted away before our eyes and died within a year. He was a big, round guy in life, but lying in his casket, it was like someone had let all the air out of a balloon. There wasn't anything left of him.
Pancreatic cancer is nasty (most cancers are), but the recent breakthroughs make me hopeful that we'll one day see a world where it won't be so devastating.
Get a daily email with the the top stories from Hacker News. No spam, unsubscribe at any time.